Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2017 | What to look for in novel CLL therapies

Kostas Stamatopoulos • 12 May 2017
iwCLL 2017
Chronic Lymphocytic Leukemia

Kostas Stamatopoulos, MD, PhD from the Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece, discusses what is important when evaluating new therapies. Duration of response to treatment and patient quality of life are two major factors when considering new therapies and managing disease. This interview was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

More from Kostas Stamatopoulos

3:19
Translating scientific advances into clinical success in CLL: satellite symposium highlights
Kostas Stamatopoulos • 19 Mar 2022
2:02
The link between the tumor microenvironment & gene expression in CLL
Kostas Stamatopoulos • 19 Mar 2022
1:46
Pathogenesis and transformation in CLL: session highlights
Kostas Stamatopoulos • 19 Mar 2022
2:54
The definition of high-risk CLL
Kostas Stamatopoulos • 19 Mar 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals